Artery Embolization vs Operation of Benign Prostate Hyperplasia
Launched by OSLO UNIVERSITY HOSPITAL · Sep 7, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two treatments for men with Benign Prostatic Hyperplasia (BPH), which causes uncomfortable urinary symptoms. The study will look at prostate artery embolization (PAE), a less invasive procedure, against traditional surgery to see which one is better in terms of how patients feel about the treatment, any complications, and recovery time. To participate, men need to have moderate to severe urinary symptoms that haven’t improved with medication for at least six months, and their prostate must be larger than 50 ml. Participants will be randomly assigned to either the embolization or surgery group.
If you join the trial, you will first have tests like a CT scan and MRI to ensure you qualify. If selected, you will receive either PAE, where tiny particles are injected into the arteries supplying the prostate, or surgery to remove prostate tissue. Participants will have follow-up visits at 3 months, 1 year, and 5 years to monitor their recovery and any complications. This study is currently recruiting participants, and it’s important to know that certain medical conditions may exclude you from participating, such as having prostate cancer or previous prostate surgery.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • LUTS from Benign Prostate Hyperplasia (BPH) with moderate and severe IPSS score (IPSS \> 8) and QoL = or \>3
- • and refractory to medical treatment for at least 6 months or the patient is unwilling to accept medical treatment
- • or BPH using permanent or intermittent catheterization
- • Prostate volume \> 50 ml
- • Signed informed consent
- Exclusion Criteria:
- • Urological disorders: evidence of clinically significant prostate cancer \[as defined by START criteria\] on prostate biopsy (27,28), prostatitis (29,30), detrusor-sphincter dyssynergia or evidence of neurogenic bladder, urethral strictures, bladder neck contracture, bladder stone or bladder cancer
- • Renal insufficiency defined as Glomerular Filtration Rate \< 30 ml/min/1,73m2
- • Known severe reactions to iodine-based contrast or gadolinium-based contrast
- • Previous prostate operation
- • CT examination reveals no access to the prostate arteries.
About Oslo University Hospital
Oslo University Hospital is a leading academic medical center in Norway, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes the development of new therapies and treatment strategies. With a multidisciplinary approach, Oslo University Hospital collaborates with various stakeholders, including researchers, healthcare professionals, and industry partners, to enhance clinical outcomes and contribute to the global medical community. Its dedication to ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and respect for participant welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oslo, , Norway
Patients applied
Trial Officials
Nils Einar Kløw, MD, PHD
Principal Investigator
Department of Radiology, Oslo University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials